BACKGROUND: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatment due to unknown symptom onset time and limited availability of advanced imaging modalities. The Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST) is a randomized controlled trial of intravenous tenecteplase 0.25 mg/kg and standard care versus standard care alone (no thrombolysis) in patients who wake up with acute ischemic stroke and can be treated within 4.5 h of wakening based on non-contrast CT findings. OBJECTIVE: To publish the detailed statistical analysis plan for TWIST prior to unblinding. METHODS: The TWIST statistical analysis plan is consistent with the Consolidating Standard of Reporting Trials (CONSORT) statement and provid...
Background Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use...
Background About one in five strokes occur during sleep (wake-up stroke). People with wake-up stroke...
Endovascular treatment has been shown to restore blood flow effectively. Second-generation medical d...
Background: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatmen...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advanced...
Background: Cooling may reduce infarct size and improve neurological outcomes in patients with ischa...
RATIONALE: Thrombolysis with intravenous alteplase is both effective and safe when administered to p...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients...
Rationale: Glyceryl trinitrate, a nitric oxide donor, is a candidate treatment for acute stroke; it ...
RationaleEndovascular treatment has been shown to restore blood flow effectively. Second-generation ...
BACKGROUND AND PURPOSE: The National Institutes of Health (NIH) estimates that stroke costs now exce...
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasmi...
Background Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use...
Background About one in five strokes occur during sleep (wake-up stroke). People with wake-up stroke...
Endovascular treatment has been shown to restore blood flow effectively. Second-generation medical d...
Background: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatmen...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advanced...
Background: Cooling may reduce infarct size and improve neurological outcomes in patients with ischa...
RATIONALE: Thrombolysis with intravenous alteplase is both effective and safe when administered to p...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients...
Rationale: Glyceryl trinitrate, a nitric oxide donor, is a candidate treatment for acute stroke; it ...
RationaleEndovascular treatment has been shown to restore blood flow effectively. Second-generation ...
BACKGROUND AND PURPOSE: The National Institutes of Health (NIH) estimates that stroke costs now exce...
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasmi...
Background Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use...
Background About one in five strokes occur during sleep (wake-up stroke). People with wake-up stroke...
Endovascular treatment has been shown to restore blood flow effectively. Second-generation medical d...